The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients
作者： Michelle Tsigoulis , Mahesh Kajil , Milan Gupta , Manoela Fb Braga , Subodh Verma
DOI:
关键词:
摘要: OBJECTIVE: To compare the effects of a 12-week treatment course rosiglitazone-based versus metformin- or glyburide-based strategy on inflammatory biomarkers and adipokine levels in hypertensive, type 2 diabetes patients.
参考文章(47)
Linda S Geiss, Deborah B Rolka, Michael M Engelgau, Elevated blood pressure among U.S. adults with diabetes, 1988-1994. American Journal of Preventive Medicine. ,vol. 22, pp. 42- 48 ,(2002) , 10.1016/S0749-3797(01)00399-3
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials JAMA Internal Medicine. ,vol. 165, pp. 1410- 1419 ,(2005) , 10.1001/ARCHINTE.165.12.1410
Giuseppe Coppola, Egle Corrado, Ida Muratori, Rosalba Tantillo, Giustina Vitale, L. Lo Coco, Salvatore Novo, Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. International Journal of Cardiology. ,vol. 106, pp. 16- 20 ,(2006) , 10.1016/J.IJCARD.2004.12.051
B. Linnemann, W. Voigt, W. Nobel, H. Janka, C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Experimental and Clinical Endocrinology & Diabetes. ,vol. 114, pp. 127- 134 ,(2006) , 10.1055/S-2006-924012
Alison K. Death, Elizabeth J. Fisher, Kristine C.Y. McGrath, Dennis K. Yue, High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis. ,vol. 168, pp. 263- 269 ,(2003) , 10.1016/S0021-9150(03)00140-0
Olivier F Bertrand, Paul Poirier, Josep Rodés-Cabau, Stéphane Rinfret, Lawrence M Title, Vladimir Dzavik, Madhu Natarajan, Juan Angel, Nuria Batalla, Natalie Alméras, Olivier Costerousse, Robert De Larochellière, Louis Roy, Jean-Pierre Després, VICTORY Trial Investigators, Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial Atherosclerosis. ,vol. 211, pp. 565- 573 ,(2010) , 10.1016/J.ATHEROSCLEROSIS.2010.06.005
Derek J. Stocker, Allen J. Taylor, Roy W. Langley, Matthew R. Jezior, Robert A. Vigersky, A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes American Heart Journal. ,vol. 153, pp. 445- ,(2007) , 10.1016/J.AHJ.2006.11.005
M. Soinio, J. Marniemi, M. Laakso, S. Lehto, T. Ronnemaa, High-Sensitivity C-Reactive Protein and Coronary Heart Disease Mortality in Patients With Type 2 Diabetes: A 7-year follow-up study Diabetes Care. ,vol. 29, pp. 329- 333 ,(2006) , 10.2337/DIACARE.29.02.06.DC05-1700
Paul M Ridker, Peter WF Wilson, Scott M Grundy, None, Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk? Circulation. ,vol. 109, pp. 2818- 2825 ,(2004) , 10.1161/01.CIR.0000132467.45278.59
J. Stamler, O. Vaccaro, J. D. Neaton, D. Wentworth, , Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. ,vol. 16, pp. 434- 444 ,(1993) , 10.2337/DIACARE.16.2.434